MicroRNAs靶向脂代谢重编程参与肝细胞癌发生的研究进展

doi:10.16352/j.issn.1001-6325.2022.12.1930

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (12): 1930-1934.doi: 10.16352/j.issn.1001-6325.2022.12.1930

MicroRNAs靶向脂代谢重编程参与肝细胞癌发生的研究进展

王玉敏¹, 陈济超^1*, 王洪权², 王金华³, 唐博²

1.航天中心医院北京大学航天临床医学院呼吸与危重症医学科,北京 100049;
2.天津医科大学肿瘤医院天津医科大学肿瘤研究所国家癌症临床医学研究中心天津市肿瘤防治重点实验室天津市恶性肿瘤临床医学研究中心胰腺肿瘤科,天津 300060;
3.中国医学科学院北京协和医学院药物研究所天然药物活性物质与功能国家重点实验室药物靶点研究与新药筛选北京市重点实验室,北京 100050

收稿日期:2021-05-11 修回日期:2021-12-31 出版日期:2022-12-05 发布日期:2022-11-23
通讯作者: ^* chen_htzxyy@sina.com
基金资助:
国家自然科学基金(81871938);北京市海淀区卫生健康发展科研培育计划(HP2021-19-50701);航天中心医院院级课题(YN202104);中国航天科工集团课题(2020-LCYL-009);航天医科科研课题(2020YK02)

Research progress of microRNAs as remodelers of lipid metabolic reprogramming in hepatocellular carcinoma

WANG Yu-min¹, CHEN Ji-chao^1*, WANG Hong-quan², WANG Jin-hua³, TANG Bo²

1. Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing 100049;
2. Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060;
3. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, CAMS & PUMC, Beijing Key Laboratory of Drug Target and Screening Research, Beijing 100050,China

Received:2021-05-11 Revised:2021-12-31 Online:2022-12-05 Published:2022-11-23
Contact: ^* chen_htzxyy@sina.com

摘要/Abstract

摘要： 代谢重编程被认为是肿瘤细胞最重要的特征之一。微小RNAs(microRNAs)是一组多功能的非编码RNA,通过脂质代谢重编程在肝细胞癌(HCC)的发生发展中发挥重要作用。本文综述了microRNAs调控肝癌脂质代谢重编程的研究进展。

关键词: 肝细胞癌, 微小RNAs, 脂代谢重编程, 肿瘤发生

Abstract: Metabolic reprogramming is considered to be one of the top characteristics of tumor cells. Ample experimental studies have shown that microRNAs, which are a group of multifunctional non-coding RNAs, play an important role in the development of hepatocellular carcinoma (HCC) through lipid metabolic reprogramming. The current review briefly introduces the recent progress of specific microRNAs targeting at lipid metabolic reprogramming in HCC, which may provide a potential strategy for clinical targeting tumor therapy.

Key words: hepatocellular carcinoma, microRNAs, lipid metabolic reprogramming, tumorigenesis

中图分类号:

R735.7

王玉敏, 陈济超, 王洪权, 王金华, 唐博. MicroRNAs靶向脂代谢重编程参与肝细胞癌发生的研究进展[J]. 基础医学与临床, 2022, 42(12): 1930-1934.

WANG Yu-min, CHEN Ji-chao, WANG Hong-quan, WANG Jin-hua, TANG Bo. Research progress of microRNAs as remodelers of lipid metabolic reprogramming in hepatocellular carcinoma[J]. Basic & Clinical Medicine, 2022, 42(12): 1930-1934.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2022.12.1930

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2022/V42/I12/1930

参考文献

[1]Nakagawa H, Hayata Y, Kawamura S, et al. Lipid metabolic reprogramming in hepatocellular carcinoma[J]. Cancers (Basel), 2018,10:447.doi: 10.3390/cancers10110447.
[2]Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight[J]. Nat Rev Cancer, 2013,13:227-232.
[3]Budhu A, Roessler S, Zhao X, et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes[J]. Gastroenterology, 2013,144:1066-1075.
[4]Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells[J]. Oncogenesis, 2016,5:e189.doi: 10.1038/oncsis.2015.49.
[5]Mosaoa R, Kasprzyk-Pawelec A, Fernandez HR, et al. The mitochondrial citrate carrier SLC25A1/CIC and the fundamental role of citrate in cancer, Inflammation and Beyond[J]. Biomolecules, 2021,11:141.doi: 10.3390/biom11020141.
[6]Zhao G, Dong L, Shi H, et al. MicroRNA-1207-5p inhibits hepatocellular carcinoma cell growth and invasion through the fatty acid synthase-mediated Akt/mTOR signalling pathway[J]. Oncol Rep, 2016,36:1709-1716.
[7]Wu H, Ng R, Chen X, et al. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway[J]. Gut, 2016,65:1850-1860.
[8]Zhang H, Feng Z, Huang R, et al. MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1[J]. Int J Oncol, 2014,45:2143-2152.
[9]Li H, Chen Z, Zhang Y, et al. MiR-4310 regulates hepatocellular carcinoma growth and metastasis through lipid synthesis[J]. Cancer Lett, 2021,519:161-171.
[10]Lin YX, Wu XB, Zheng CW, et al. Mechanistic investigation on the regulation of FABP1 by the IL-6/miR-603 signaling in the pathogenesis of hepatocellular carcinoma[J]. Biomed Res Int, 2021:8579658.doi: 10.1155/2021/8579658.
[11]Bai PS, Xia N, Sun H, et al. Pleiotrophin, a target of miR-384, promotes proliferation, metastasis and lipo-genesis in HBV-related hepatocellular carcinoma[J]. J Cell Mol Med, 2017,21:3023-3043.
[12]Zare M, Panahi G, Koushki M, et al. Metformin reduces lipid accumulation in HepG2 cells via downregulation of miR-33b[J]. Arch Physiol Biochem, 2022,128:333-340.
[13]Yuan P, Mu J, Wang Z, et al. Down-regulation of SLC25A20 promotes hepatocellular carcinoma growth and metastasis through suppression of fatty-acid oxidation[J]. Cell Death Dis, 2021,12:361.doi:10.1038/s41419-021-03648-1.
[14]Liu Y, Lu LL, Wen D, et al. MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming[J]. J Hematol Oncol, 2020,13:12.doi: 10.1186/s13045-019-0841-3.
[15]Vanni S. Intracellular lipid droplets: from structure to function[J]. Lipid Insights, 2017,10:1178635317745518.doi: 10.1177/1178635317745518.
[16]Koizume S, Miyagi Y. Lipid droplets: akey cellular organelle associated with cancer cell survival under normoxia and hypoxia[J]. Int J Mol Sci, 2016,17.doi: 10.3390/ijms17091430.
[17]Baenke F, Peck B, Miess H, et al. Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development[J]. Dis Model Mech, 2013,6:1353-1363.
[18]Hsu SH, Wang B, Kota J, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver[J]. J Clin Invest, 2012,122:2871-2883.
[19]Guo XY, He CX, Wang YQ, et al. Circular RNA profiling and bioinformatic modeling identify its regulatory role in hepatic steatosis[J]. Biomed Res Int, 2017,2017:5936171.doi: 10.1155/2017/5936171.
[20]Zhang Q, Ma XF, Dong MZ, et al. MiR-30b-5p regulates the lipid metabolism by targeting PPARGC1A in Huh-7 cell line[J]. Lipids Health Dis, 2020,19:76.doi: 10.1186/s12944-020-01261-3.
[21]Yan S, Yang XF, Liu HL, et al. Long-chain acyl-CoA synthetase in fatty acid metabolism involved in liver and other diseases: an update[J]. World J Gastroenterol, 2015,21:3492-3498.
[22]Cui M, Wang Y, Sun B, et al. MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA[J]. Biochem Biophys Res Commun, 2014,444:270-275.
[23]Cui M, Xiao Z, Sun B, et al. Involvement of cholesterol in hepatitis B virus X protein-induced abnormal lipid metabolism of hepatoma cells via up-regulating miR-205-targeted ACSL4[J]. Biochem Biophys Res Commun, 2014,445:651-655.
[24]Guo J, Fang W, Sun L, et al. Ultraconserved element uc.372 drives hepatic lipid accumulation by suppressing miR-195/miR4668 maturation[J]. Nat Commun, 2018,9:612.doi: 10.1038/s41467-018-03072-8.

MicroRNAs靶向脂代谢重编程参与肝细胞癌发生的研究进展

Research progress of microRNAs as remodelers of lipid metabolic reprogramming in hepatocellular carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	周岚, 张生贵, 胡祖梁, 王添贤, 岳鹏鹏, 于鸿浩. 基于CRISPR/Cas9系统高效编辑小鼠miR let-7a[J]. 基础医学与临床, 2022, 42(6): 857-863.
[2]	赵钰珊, 冀梦蝶, 董昱诚, 郭鑫, 宋博渊, 陈阳. 肝细胞癌中EZH2基因相关的表观遗传调控机制[J]. 基础医学与临床, 2022, 42(6): 864-870.
[3]	张悦怡, 李美姿, 杨莹韵, 杨爱明. 含TPR干扰素诱导蛋白在消化系统肿瘤中作用的研究进展[J]. 基础医学与临床, 2021, 41(11): 1662-1665.
[4]	吴娜, 王东, 白咸勇. 细胞自噬与肝细胞癌的研究进展[J]. 基础医学与临床, 2021, 41(10): 1514-1517.
[5]	倪安妮, 梁清洋, 姚鸿飞, 李根亮, 唐玉莲. 花生四烯酸代谢基因对小鼠肝细胞癌中环氧化酶P450途径的影响[J]. 基础医学与临床, 2020, 40(8): 1053-1058.
[6]	曹明月, 李高翔, 陈昱竹, 黄薇, 杨楠, 刘雁勇. 儿茶酚胺类应激激素促进小鼠肝癌细胞系H22中G₀期细胞周期再入[J]. 基础医学与临床, 2020, 40(7): 897-902.
[7]	刘娜斯, 曹明月, 吴友明, 黄薇, 杨楠, 刘雁勇. HSP90抑制剂抑制糖酵解并促进小鼠肝癌细胞系H22凋亡[J]. 基础医学与临床, 2020, 40(7): 912-916.
[8]	张新然, 张弋, 高慧儿, 强兆艳, 李咏梅. Shc3高表达抑制人肝癌细胞系凋亡并参与肝癌耐药[J]. 基础医学与临床, 2020, 40(4): 473-478.
[9]	黄海良, 丁伟伟, 李冬雪. CRNDE过表达促进人肝癌细胞系HepG2增殖和迁移[J]. 基础医学与临床, 2020, 40(2): 219-223.
[10]	侯彭姣邓艳春梁娜刘长征. miR-449b介导5-氟尿嘧啶/顺铂抑制肝癌细胞的迁移[J]. 基础医学与临床, 2017, 37(6): 792-796.
[11]	张静宇杨芳芳李京敏刘春晓白咸勇. 羟基红花黄色素A抑制H22小鼠肝癌移植瘤血管生成及减少MMP-3的表达[J]. 基础医学与临床, 2017, 37(1): 71-75.
[12]	杜义江肖长义. 微环境与肝癌发病机制的研究进展[J]. 基础医学与临床, 2015, 35(2): 248-252.
[13]	李艳沈飞阳马礼丹张艳青. 竞争性内源RNA与肿瘤发生的研究进展[J]. 基础医学与临床, 2015, 35(11): 1549-1553.
[14]	范瑞琦揭克敏肖影群刘卓琦王蒙蒙罗达亚. 肝脏非可控病毒感染性炎性反应恶性转化过程中microRNA的作用[J]. 基础医学与临床, 2014, 34(8): 1133-1137.
[15]	孙倩张宏冰. 丙酮酸激酶M2 (PKM2)在肿瘤代谢和发生中的作用[J]. 基础医学与临床, 2012, 32(5): 462-467.